INBS vs PATH · rev $4.2M vs P/E 19, rev $1.61B
Intelligent Bio Solutions Inc. (INBS) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Intelligent Bio Solutions Inc. (INBS) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported INBS revenue for 2026-06-30 was $4.2M. Net income was -$12.4M. Revenue was up 38.1% from 2025-06-30 to 2026-06-30. INBS currently screens at market cap $5.9M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
INBS currently screens at market cap $5.9M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the INBS and PATH stock pages for the full models.
Not investment advice.